537 filings
6-K
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
6-K
BLRX
Bioline Rx Ltd
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
6-K
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
ijq8p6uff270e
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
k1r v2oc6q4dbeykcub9
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
eg1hojmlxv39
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
x2yij2yroy8vf69aj2z
16 Feb 24
Current report (foreign)
7:07am
EFFECT
bdt1ea2 o1t
8 Jan 24
Notice of effectiveness
12:15am
S-8
c507rf ttjnjmm
29 Dec 23
Registration of securities for employees
4:20pm
F-3
vbnzg4sx
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
jzcp t3b8xcr
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
m6lk1k nvcuabv
12 Dec 23
Current report (foreign)
7:07am
6-K
78lc0esw cmbt
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
SC 13D
hqdead qs163id4z1
26 Oct 23
BioLineRx / Hong Seng Technology ownership change
2:18pm
6-K
rib9kpkz
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
skj1y15qau
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
6-K
4ky4p58iiohs
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am